Thu, Sep 18, 2014, 1:23 PM EDT - U.S. Markets close in 2 hrs 37 mins


% | $
Quotes you view appear here for quick access.


  • ukwildcat7 ukwildcat7 Apr 29, 2011 12:30 PM Flag

    Rabin's Latest Blog 4/28/11


    As you are no doubt aware, ACT is quickly evolving from a development-stage biotechnology company to a clinical-stage company developing regenerative medicine. We now have two of the three total FDA clearances for embryonic stem cell-based clinical trials that have ever been issued, and we are eagerly anticipating starting these trials in the first half of this year.

    Since the two clinical trials are likely to garner a lot of media attention, we have decided to retain the services of Russo Partners. In business for 23 years, Russo Partners is the best-in-breed of healthcare and life science PR/corporate communications firms. As an added benefit, Russo Partners (formerly Noonan Russo) worked with ACT during an earlier era (2000 – 2001), so knows the company well.

    We are pleased to have Russo Partners on board and look forward to their assistance as we share major future developments.

    Thank you.

    Gary Rabin
    Interim Chairman and CEO
    Advanced Cell Technology, Inc.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.08150.0000(0.00%)Aug 27 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.